Oppenheimer reiterates Outperform on Connect Biopharma; $5 target
Oppenheimer maintained an Outperform rating on Connect Biopharma and kept a $5.00 price target, implying 278.8% upside versus a Sep 21 close of $1.32.
Oppenheimer maintained an Outperform rating on Connect Biopharma and kept a $5.00 price target, implying 278.8% upside versus a Sep 21 close of $1.32.